Helping patients reclaim a life of possibility
Since 2015 Lise-Lott has been Chairman of the Swedish Blood Cancer Association, previously Chairman of the Blood Cancer Society in Stockholm and now the president of Myeloma Patients Europe (MPE). Lise-Lott is very active in policy-related issues within the Swedish cancer care area. She focuses on access to new drugs for haematological disorders (especially myeloma),…
The European Medicines Agency (EMA) has recommended a conditional marketing authorisation in the European Union (EU) for teclistamab for the treatment of adult patients with relapsed and refractory myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment. Teclistamab, alternatively known…
Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here. Alternatively known under the branded name “Revlimid”, lenalidomide is a drug licensed and commonly used in the treatment of myeloma – in newly diagnosed, maintenance and relapsed settings. Lenalidomide…
Today Myeloma Patients Europe (MPE) published our 2021: Year in Review, a snapshot of the major accomplishments from the past year. In 2021, MPE launched two projects that will provide distinct and indispensable resources for the patient community: the launch of the redesigned Myeloma Access Atlas, helping the patient community to advocate more effectively…
Myeloma Patients Europe (MPE) has today relaunched the Myeloma Access Atlas, an online platform designed to provide myeloma and AL amyloidosis patient advocates with the information and tools needed to work effectively on access issues. Explore the Platform here. The Atlas provides country-specific and comparative information on European healthcare systems, including data on system…
Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma. If you are interested, please read the information below and complete the following application form. Deadline for submission is 3 pm CET on Friday 5th of November 2021